MedTrace Logo

Correlation Between Serum Nociceptin and Sympathetic Nerve Activity in Diabetic Patients With MAFLD

NCT07663682 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-06-23

No results posted yet for this study

Summary

This observational study aims to investigate the relationship between serum nociceptin levels and sympathetic nervous system activity in patients with both type 2 diabetes mellitus (T2DM) and metabolic associated fatty liver disease (MAFLD). A total of 100 participants, aged 18 to 75 years, who are scheduled for laparoscopic cholecystectomy at our hospital will be enrolled. Participants will be divided into two groups: 50 patients with both T2DM and MAFLD, and 50 healthy controls without either condition. The main goals are to determine if nociceptin levels correlate with liver function, liver fibrosis severity, and sympathetic nerve activity. During a single study visit, a 5 mL blood sample will be collected to measure serum nociceptin and norepinephrine (a marker of sympathetic activity). Routine clinical data will also be retrieved from medical records. This study involves no experimental drugs or devices, and all participants will continue to receive standard care. The findings may identify nociceptin as a potential diagnostic biomarker for this comorbidity.

Conditions

  • Diabetes Mellitus, Type 2
  • Metabolic Associated Fatty Liver Disease

Sponsors & Collaborators

  • Second Hospital of Shanxi Medical University

    lead OTHER

Principal Investigators

  • Yi Han, PhD · Second Hospital of Shanxi Medical University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2026-06-05
Completion
2026-06-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07663682 on ClinicalTrials.gov